In early trade on Friday, these stocks dropped by as much as 3%, with the Nifty Auto and Nifty Pharma indices trading lower ...

Investors in pharma and auto stocks are anxious ahead of the April 2 deadline for US tariffs. Despite a 6% fall over three ...

Addressing the calculation of patent term extensions (PTEs) under the Hatch-Waxman Act, the US Court of Appeals for the Federal Circuit affirmed ...

U.S. President Trump imposes 25% tariff on auto imports, spotlight on pharma imports, Indian industry at risk.

The growth of the India generic drugs market is supported by proactive government policies aimed at bolstering the pharmaceutical sector. Initiatives such as the “Make in India” campaign and ...

On March 13, 2025, the Federal Circuit issued a decision in Merck Sharp & Dohme B.V. v. Aurobindo Pharma USA, Inc., No. 23-2254 (Fed. Cir. 2025) ...

“We are excited to collaborate with Scienture to enhance its commercial effectiveness,” said Paul Mignon, President, Deployment Solutions, Syneos Health. “Our team is committed to delivering tailored ...

Violations highlight growing concerns over the unchecked rise in medicine prices and their impact on affordability ...

Stocks like Reliance Industries, Apollo Hospitals Enterprise, Power Grid Corporation, Allied Blenders and Distillers, ...

Curateq Biologics, a wholly owned subsidiary of Aurobindo Pharma, has allotted 4,125,055 Compulsory Convertible Preference Shares (CCPSs) of Rs.10/- each to Dr. Satakarni Makkapati on 20 March 2025.

Aurobindo Pharma Ltd - Allotment Of Compulsory Convertible Preference Shares To Dr. Satakarni Makkapati By Curateq Biologics Private Limited, A Wholly Owned Subsidiary Of The Company.